Literature DB >> 17433064

Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer.

P Harter1, K Gnauert, R Hils, T G Lehmann, A Fisseler-Eckhoff, A Traut, A du Bois.   

Abstract

Para-aortic lymphadenectomy is part of staging in early epithelial ovarian cancer (EOC) and could be part of therapy in advanced EOC. However, only a minority of patients receive therapy according to guidelines or have attendance to a specialized unit. We analyzed pattern of lymphatic spread of EOC and evaluated if clinical factors and intraoperative findings reliably could predict lymph node involvement, in order to evaluate if patients could be identified in whom lymphadenectomy could be omitted and who should not be referred to a center with capacity of performing extensive gynecological operations. Retrospective analysis was carried out of all patients with EOC who had systematic pelvic and para-aortic lymphadenectomy during primary cytoreductive surgery. One hundred ninety-five patients underwent systematic pelvic and para-aortic lymphadenectomy. Histologic lymph node metastases were found in 53%. The highest frequency was found in the upper left para-aortic region (32% of all patients) and between vena cava inferior and abdominal aorta (36%). Neither intraoperative clinical diagnosis nor frozen section of pelvic nodes could reliably predict para-aortic lymph node metastasis. The pathologic diagnosis of the pelvic nodes, if used as diagnostic tool for para-aortic lymph nodes, showed a sensitivity of only 50% in ovarian cancer confined to the pelvis and 73% in more advanced disease. We could not detect any intraoperative tool that could reliably predict pathologic status of para-aortic lymph nodes. Systematic pelvic and para-aortic lymphadenectomy remains part of staging in EOC. Patients with EOC should be offered the opportunity to receive state-of-the-art treatment including surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17433064     DOI: 10.1111/j.1525-1438.2007.00931.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  27 in total

1.  Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes.

Authors:  Mohamed Ibrahim Fahim; Abdelmaksoud Mohamed Ali; Rasha Mahmoud Allam
Journal:  Indian J Surg Oncol       Date:  2019-12-02

2.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Authors:  Takafumi Oshita; Hiroaki Itamochi; Ryuichiro Nishimura; Fumitaka Numa; Kazuhiro Takehara; Masamichi Hiura; Hirotoshi Tanimoto; Jun Noma; Ryoji Hayase; Akihiro Murakami; Hideo Fujimoto; Yasunobu Kanamori; Fuminori Kitada; Keiji Shitsukawa; Makoto Nagaji; Yukihisa Minagawa; Michihisa Fujiwara; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2012-10-17       Impact factor: 3.402

3.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

4.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

Review 5.  Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors:  Pierluigi Benedetti Panici; Andrea Giannini; Margherita Fischetti; Francesca Lecce; Violante Di Donato
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

Review 6.  [Intraoperative frozen sections in diseases of the female genital tract].

Authors:  S Lax; K Tamussino; K Prein; P Lang
Journal:  Pathologe       Date:  2012-09       Impact factor: 1.011

7.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

8.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?

Authors:  Majdi Imterat; Philipp Harter
Journal:  J Gynecol Oncol       Date:  2021-04-19       Impact factor: 4.401

10.  Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Authors:  Paula Cunnea; Sally Gowers; James E Moore; Emmanuel Drakakis; Martyn Boutelle; Christina Fotopoulou
Journal:  Converg Sci Phys Oncol       Date:  2017-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.